BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26844708)

  • 1. Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
    Signorelli M; Bogani G; Ditto A; Martinelli F; Chiappa V; Lopez C; Scaffa C; Lorusso D; Raspagliesi F
    Minerva Ginecol; 2016 Oct; 68(5):536-43. PubMed ID: 26844708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
    Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
    S Chapman J; Roddy E; Panighetti A; Hwang S; Crawford B; Powell B; Chen LM
    Clin Breast Cancer; 2016 Dec; 16(6):494-499. PubMed ID: 27495996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.
    Holman LL; Friedman S; Daniels MS; Sun CC; Lu KH
    Gynecol Oncol; 2014 May; 133(2):283-6. PubMed ID: 24582866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
    Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
    J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
    Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
    Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic salpingectomy with delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in BRCA1/2 mutation carriers: women's point of view.
    Mohr-Sasson A; Dadon T; Perri T; Rosenblat O; Friedman E; Korach J
    Menopause; 2023 May; 30(5):476-479. PubMed ID: 36917763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
    Perez L; Webster E; Bull L; Brewer JT; Ahsan MD; Lin J; Levi SR; Cantillo E; Chapman-Davis E; Holcomb K; Rosenberg SM; Frey MK
    Gynecol Oncol; 2023 Jun; 173():106-113. PubMed ID: 37116391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
    Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA
    Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?
    Greene MH; Mai PL; Schwartz PE
    Am J Obstet Gynecol; 2011 Jan; 204(1):19.e1-6. PubMed ID: 20619389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.